EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

COVID‐19 and Oncofertility: No SARS‐CoV‐2 in Semen but Inflammation Seems to Affect Sperm Parameters

Laure Chaput, Hanae Pons-Rejraji, Hélène Chabrolles, Mélanie Fiot iD, Cécily Lucas, Bruno Pereira, Benjamin Bonnet, Rahaf Haj Hamid, Aurélie Rives-Feraille, Olivier Binois, Lucile Ferreux, Béatrice Delepine und 8 weitere

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.70070 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Laure Chaput und 19 weiteren Autor:innen. Beteiligte Einrichtung: CHU Clermont-Ferrand, Service AMP-CECOS (Centre d'Etude et de Conservation des Œufs et du Sperme Humain), Clermont-Ferrand, France. Hauptthemen laut MEDLINE: COVID-19, Semen, Spermatozoa, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This research was supported by the Ferring grant, French Biomedicine agency grant, and Michelin company., Ferring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID‐19 pandemic, driven by SARS‐CoV‐2, led authorities to recommend halting assisted reproductive technology programs, focusing instead on fertility preservation, for cancer patients. The presence of SARS‐CoV‐2 in semen remains controversial. This multicentric prospective cohort study, conducted across 12 university medical centers, aimed to determine if SARS‐CoV‐2 is present in spermatozoa/seminal plasma in cancer patients by RT‐PCR and to assess its impact on standard semen parameters. The levels of cytokines and TNF‐α were measured in seminal fluid by ELISA. We enrolled 129 men who underwent sperm cryopreservation between July 7, 2020, and June 30, 2021. The 63 were included and tested for COVID‐19 in nasal swab samples by RT‐PCR and/or by serology. All patients were asymptomatic on the day of semen collection: 50 were uninfected, 8 had a positive nasal swab (PCR+) and 5 were seropositive. SARS‐CoV‐2 RNA was not detected in the seminal fluid or spermatozoa. Ejaculate volume was significantly lower in the PCR+ group compared to the uninfected group (median [IQR]: 2.6 mL [1.6–3.4] vs. 4.6 mL [2.6–5.2] p < 0.05). Total and progressive motility were lower in the PCR+ group compared to the seropositive group (32.5% [25.0–45.0] vs. 50% [49.0–55.0] p < 0.05, and 22.5% [10.0; 32.5] vs. 44.5% [40–49] p < 0.05). Higher TNF‐α level was observed in the PCR+ group (1.9 pg/mL [0–3.9]) compared to the uninfected group (0 pg/mL [0–0.4]) p < 0.05. Although SARS‐CoV‐2 was not detected in the sperm samples of cancer patients who were PCR+, the infection appears to impact sperm parameters, likely due to inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SemenSpermatozoaSARS-CoV-2NeoplasmsHumansMaleAdultProspective StudiesMiddle AgedInflammationCytokinesFertility PreservationCryopreservationSemen AnalysisTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

SARS‐CoV‐2cancerfertility preservationsemen parametersseminal fluid inflammation

Substanzen

CytokinesTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • CHU Clermont-Ferrand, Service AMP-CECOS (Centre d'Etude et de Conservation des Œufs et du Sperme Humain), Clermont-Ferrand, France.
  • Université Clermont Auvergne, INSERM 1240, IMoST (Imagerie Moléculaire et Stratégies Théranostiques), Clermont-Ferrand, France.
  • CHU Clermont-Ferrand, Laboratoire de Virologie, Clermont-Ferrand, France.
  • CHU Clermont-Ferrand, Délégation Recherche Clinique and Innovation, Méthodologie, Biostatistique, Data Management, Clermont-Ferrand, France.
  • CHU Clermont-Ferrand, laboratoire d'Immunologies, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Laboratoire de Biologie de la Reproduction Hôpital Tenon, Paris, France.

ORCID-Profile: Mélanie Fiot, Florence Brugnon

Förderung

  • This research was supported by the Ferring grant, French Biomedicine agency grant, and Michelin company.
  • Ferring

Zitieren

APA

Chaput, L., Pons-Rejraji, H., Chabrolles, H., Fiot, M., Lucas, C., Pereira, B., Bonnet, B., Haj Hamid, R., Rives-Feraille, A., Binois, O., Ferreux, L., Delepine, B., Koscinski, I., Lichtblau, I., Giscard d'Estaing, S., Bendayan, M., Saias-Magnan, J., Lousqui, J., Henquell, C., & Brugnon, F. (2024). COVID‐19 and Oncofertility: No SARS‐CoV‐2 in Semen but Inflammation Seems to Affect Sperm Parameters. Journal of Medical Virology. https://doi.org/10.1002/jmv.70070

Vancouver

Chaput L, Pons-Rejraji H, Chabrolles H, Fiot M, Lucas C, Pereira B, et al. COVID‐19 and Oncofertility: No SARS‐CoV‐2 in Semen but Inflammation Seems to Affect Sperm Parameters. Journal of Medical Virology. 2024. doi:10.1002/jmv.70070

BibTeX
@article{Chaput2024,
  author = {Chaput, Laure and Pons-Rejraji, Hanae and Chabrolles, Hélène and Fiot, Mélanie and Lucas, Cécily and Pereira, Bruno and Bonnet, Benjamin and Haj Hamid, Rahaf and Rives-Feraille, Aurélie and Binois, Olivier and Ferreux, Lucile and Delepine, Béatrice and Koscinski, Isabelle and Lichtblau, Isabelle and Giscard d'Estaing, Sandrine and Bendayan, Marion and Saias-Magnan, Jacqueline and Lousqui, Johanna and Henquell, Cécile and Brugnon, Florence},
  title = {COVID‐19 and Oncofertility: No SARS‐CoV‐2 in Semen but Inflammation Seems to Affect Sperm Parameters},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.70070}
}
Kostenlos starten →